Healthcare, Biotechnology & Pharmaceuticals

The World Health Organization’s definition of health says that it is "a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity."

Managing health, in terms of health indicators such as life expectancy, infant mortality and health insurance coverage, and sustaining a well functioning health system is a challenge that requires the cooperation of many parties across public and private sectors.

Healthcare organizations operate in a dynamic diagnostics and therapeutics ecosystem, challenged to incorporate scientific and technological driven processes, and deliver managed diagnosis and therapy to the discerning consumer with rising health awareness.

The Healthcare, Pharma, and Life Science industries, comprise of the manufacture of pharmaceuticals for human and veterinary use, medical equipment diagnostic laboratories, hospitals, and nursing and residential care facilities and related supplies.

The healthcare service providing business, health insurance, and pharmaceutical business are all at transforming to improve healthcare outcomes and efficiency, as well as offer easier access to healthcare services and cheaper healthcare to deliver the maximum value to patients.

The healthcare industry has been expanding owing to the growing demands for more effective drugs, and its patient-centric and value-driven care approach.

As consumers assume greater responsibility for out-of-pocket expenses and better managing their own health through a variety of consumer engagement initiatives, the quest is for a value-based health system, and healthcare organizations already incorporate digital technology for monitoring and communicating with patients, and smart patient engagement tools in improving quality, experience, and engagement.

An aging population and the evolution of new diseases has fuelled the need to better and faster healthcare access.

Demographic and lifestyle changes: As the population ages, there will be an increased demand for healthcare – both in terms of drugs and care (assisted living). Growing awareness of health and wellbeing issues is also likely to have a significant impact on the demand for health-related goods and services.

Increasing prevalence of chronic conditions, staffing shortages, and other industry challenges are accelerating investments in connected health technology to deliver care more efficiently and to engage more effectively. New products and innovations like telemedicine and point of care devices are gaining ground.

Integration of IT and innovations in the field of next-generation sequencing, IoT, 3D Printing, and Artificial Intelligence are some of the recent developments fuelling market growth, and driving breakthrough developments in the industry.

By 2020, 40% of healthcare providers will leverage machine learning and AI-algorithm advances to improve their cybersecurity capabilities with automated threat detection.
By 2020, adoption rates of IoT-enabled asset tracking and inventory management systems in hospitals will have doubled worldwide, improving patient safety, staff satisfaction, and operational efficiency.
IDC Health Insights

The remote monitoring devices point-of-care (POC) devices and fitness band are increasingly being adopted.

The advancement in non-invasive technologies has reduced the cost of treatment and shortened the recovery time.

As robotic technology matures, surgical robotics are becoming widespread to enhance patient outcomes by augmenting physician efficiency and eliminating medical errors, with a view to reducing the cost of surgery.

The rapid adoption of insulin pumps, artificial pacemakers, coronary stents and other mobility assist devices has contributed significantly to enhance the clinical outcomes. The workflow efficiencies have also increased due to integration of various Electronic Health Records (EHR) and Electronic Medical Records (EMR) of the patients.

In the therapeutic area, spending is on the rise across a broad range of R&D initiatives with several therapies transitioning to the final stage of clinical trials and nearing commercial launch.

The analytical and scientific instrumentation industry has evolved significantly over the past few decades, in terms of miniaturization, and automation, which offer high-throughput analysis and ease of operation.

With many drugs going off-patent, and rising government spending on pharmaceutical R&D in emerging nations, the drug development industry is one of the biggest users of analytical and scientific instrumentation and solutions, as pharmaceutical companies are investing heavily in the discovery and development of novel drugs.

Our research studies cover major therapeutic areas, such as paediatrics, cardiovascular, orthopedics, gynecology, hematology, neurology, dental, among others. Also cover areas such as drug and device combination, dental equipment market, respiratory therapy market, infusion therapy market, neurostimulators, eye related surgical technologies.

Our studies on healthcare services offer insights into the prevailing trends and opportunities in this sector, comprising of management, leadership, administration, and organization of healthcare networks to keep pace with the recent developments.

Data in the health industry cover health spending, hospital and physician infrastructure, and information on modern medical technology, diseases and health conditions, including prevention and therapy. Among the most commonly known preventions are all types of vaccinations which should prevent a possible disease in the future. Medication makes up a substantial part of therapies.

The market coverage includes pharmaceutical drugs such as cardiovascular drugs, gastrointestinal drugs, hematology drugs, genito-urinary drugs, and other drugs used to treat cardiovascular diseases, rare genetic disorders, infections, metabolic disorders, cancers, respiratory diseases and others.

We provide data on the pharma-pipeline and help drug developers identify key growth areas in the drug pipeline.

We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behaviour of all stakeholders — patients, providers, manufacturers and others — around these interventions, as to ensure efficiency and affordability of healthcare services.

Healthcare providers must meet increasingly high standards of clinical excellence and compliance, which puts pressure on limited resources and budgets.

Managing resources and budgets to secure the best clinical and patient outcomes requires focus and specialisation.

Pervasive challenges in the health care industry have prompted profound transformation in how health care is accessed, delivered and financed, and the competitive focus has shifted on administrative efficiency and population management

The complexity of this new landscape will present health plans with a considerable set of challenges.

They must consider medical management and network management strategies to manage the new population effectively and consider enhancements to their enablement technologies and business intelligence platforms to operate efficiently.

  • These changes are opening opportunities for hospitals, health insurers and other health care-focused organizations to rethink strategies — and find innovations in lowering costs while delivering exceptional value.

  • In the face of escalating costs, companies in all healthcare sectors are reassessing how best to serve and sustain growth.

Pursuing growth strategies and achieving competitive advantage are the top two drivers according to 67% and 58% of healthcare respondents respectively to an IDC Health Insights survey.

The digital imperative in healthcare is to create a connected value-based health system that is focused on outcomes-based models

The trend is on shifting from sick care to health care with an emphasis on preventive care and population health management.

And the ability to leverage clinical and financial data will help healthcare organizations create a competitive advantage.

Digital transformation is focused on scientific and technological innovation in pursuing operational excellence and improving business outcomes, by taking advantage of cloud computing and data storage, mobile devices, RPA, IoT, AI, and analytics to streamline operations and communications, and simplify work in speeding up new treatments and cures for disease.

Technology Trends

  • E health and the use of patient-centric, integrated IT networks

  • Personalised Health IT

  • Intelligent devices and expert systems –IoT collaborative hubs

  • Rise of the Infomediary and CyberPhysician, supported by SMART cards, retinal scans

  • Use of Big Data

  • Employee experience (EX) driven applications

  • Self Learning Software – Machine learning

  • Digital Employees

  • Insight Driven Business

  • Immersive Customer Experience (CX)

  • Data management and security technologies that enable contextual privacy

  • Public Cloud accelerating business innovation

  • Increased automation

  • Conversational Platforms

  • Telehealth

  • “P4 Medicine” – Predictive, Preventative, Personalised and Participatory – driven by social media-led participation platforms

  • Remote consultation and home monitoring of vital signs

  • Use of genetic screening and pharmacogenetics

  • Further use of Minimally Invasive Surgery

  • Use of robotics

  • Augmented and Virtual reality applications

  • Automated Dispensing

Enhancing innovation, reducing costs, widening market access, and changing sales models are seen as major impacts.

Pharmaceutical companies are facing two major challenges: the digital consumer demand for faster, patient-centric, outcome-based medicines; and the pressure for reduced drug prices.

Leading organizations develop a plan of action that encompasses brands, allocate their resources accordingly, review plans regularly and make changes as needed.

Collaboration across the organization is key. Leading companies are building cross-functional teams. Resources that were allocated to each brand are instead pooled, allowing the organization to focus its energies and resources where they can be put to best use.

Brand teams and commercial operations teams work together, getting the right message to the right people based on immediate market feedback.

To be effective, in market penetration with prescribers and patients and reap better outcomes, an agile sales force has to have an accurate picture of the interdependencies that underlie today’s health marketplace. That requires not only commercial agility in gathering the necessary data about patients, providers and pharmacies, but also analyzing it to identify key points of interaction in each geography.

Taking a comprehensive view, companies can work to get a new product on formulary, sales forces can be moved to key points of impact along the value, then connect with the doctors who will write the prescriptions and the pharmacy systems that will stock the product.

Trends in luring the physicians with personal incentives and benefits, is negatively impacting the reputation of the industry as well as the morale of its sales force. As a result, pharmaceutical companies are exploring for increasing the effectiveness of their marketing and sales tactics, in regaining their reputation, and increasing their sales.

The market covers healthcare services such as medical and diagnostic laboratory services, dental services, home health care and residential nursing care services, residential substance abuse and mental health facilities and other healthcare services.

Healthcare services is a large industry, creating 16 million jobs in the United States.

Source: CITIC Capital

China is the second largest healthcare market in the world and is one of the fastest growing healthcare markets in the world.

China's aging population and urbanization are expected to be key growth drivers for China's healthcare market. These factors coupled with rising Chinese wages and improving living conditions, are expected to fuel market growth.

Financing is a particularly crucial issue for health systems. Primary financial sources of health systems around the world are taxes, public and private health insurances.

The largest share of U.S. healthcare provision and spending comes from governmental programs like Medicare, Medicaid, Tricare, and private healthcare.

Physicians and hospitals are the cornerstones of every healthcare system. Care and support is an important segment, for the elderly and disabled.

Elderly care has become an increasingly discussed issue due to the fact that populations in many developed countries have a disproportionate number of old people. In the United States, some 40 million persons are 65 years and older.

According to some projections, the number of older people in the United States will be twice as much in 2030 as it was in 2000. As a result, there will be an increasing need for caregivers and care facilities in the future.

US health systems and hospitals are turning to telehealth — including video doctor visits and remote patient monitoring tech— as a tool to extend care into patients' homes to improve outcomes, while reducing costs, and is projected to grow about 7% annually from 3 billion to 3 billion by 2026 — outpacing growth of hospital care (+5.3% annually) and physician services (+5.6% annually).

Veterinary Healthcare: The veterinary healthcare market covers diagnosis, treatment and prevention of diseases in animals. The establishments include centers that provide veterinary services, veterinary medical equipment manufacturers and animal medicine manufacturers.

The medical technology industry is a key part of the healthcare sector. It includes, most of all, medical devices and medical technology products, such as pacemakers, imaging instruments, dialysis machines and implants which simplify the prevention, diagnosis and treatment of diseases.

According to Statista, the global medtech industry’s market size stands at approximately 350 billion U.S. dollars, with both United States and Western Europe generating the largest share of the global medtech revenue. China is expected to become more prominent within the global medical technology industry. Industry outlooks predict that demand for medical devices in major regions will increase until 2020.

Leading medical technology companies include, Johnson & Johnson Medical Devices & Diagnostics, General Electric Healthcare and German Fresenius Group. Medical technology advances have led to a transformation in patient care by enabling a greater focus on clinical outcomes. Minimally invasive or non-invasive medical technologies, telemedicine, capsule endoscopy and drug eluting stents, not only shorten recovery time but also lower medical costs, while improving clinical outcomes.

Aging populations, the growing challenge of chronic diseases, and the expanding needs for lifestyle medical procedures, indicate that demand for medical technology products should grow in the near future.

According to Global Market Insights research, taking into account the rising prevalence of chronic diseases, a marked increase in consumer awareness levels, supportive regulatory policies, the gradual increase in the involvement of medical product manufacturers in reprocessing activities have driven the U.S. reprocessed medical devices market share augmentation.

The medical devices market covers medical equipment used in diagnosis, treatment and monitoring of medical conditions including in-vitro diagnostic devices, cardiovascular devices, ophthalmic devices, dental equipment and supplies, hospital supplies and other medical devices.

Medical devices market research includes cardiovascular devices, orthopedic devices, surgical devices, therapeutic devices, neurostimulators, mobility assist devices, and self diagnostic devices.

Minimally Invasive & Non-Invasive Surgery

The market is destined for fast growth due to the increasing demand for painless treatment and reduced post-operative stay.

Minimally Invasive & Non-Invasive Surgery product market: surgical devices, endosurgical equipment, electrosurgical equipment, monitoring and visualization systems

Minimally Invasive & Non-Invasive Surgery application market: orthopaedic surgery, cosmetic surgery, vascular surgery, urology surgery, gastrointestinal surgery, gynecology surgery, obesity surgery, thoracic surgery

Minimally Invasive & Non-Invasive Surgery technology market: laparoscopy surgery, transcatheter surgery, non-visual imaging and medical robotics

Minimally Invasive & Non-Invasive Surgery end-user market: hospital surgical departments, outpatient surgery centers, medical schools

Non-Invasive monitoring

The monitoring devices market that covers a wide of products, ranging from glucose monitors and heart-rate meters to cancer detecting devices, facilitate early disease detection, and greater patient comfort.

Medical Imaging, Clinical Diagnostics & Laboratory Equipment

Improvements in laboratory equipment are a must for precise diagnosis. Our market analysis offer insights into trends to help manufacturers assess the dynamic landscape of the laboratory equipment sector and improve decision making.

Clinical Diagnostics include molecular diagnostics, reagent market, services market, in-vitro diagnostics (IVD), clinical laboratory instrumentation, Point-of-Care and other markets.

Our studies on medicinal imaging encompass medical imaging devices and diagnostic technologies used in the healthcare industry.
We analyze the different segments of the diagnostic imaging market such as computed tomography, magnetic resonance imaging, and positron emission tomography.
Our reports on healthcare diagnostics cover clinical, radiological, laboratory, remote diagnostics, with a focus on identifying upcoming trends and enabling companies make informed decisions to sustain growth.

Drug Delivery Devices

Drug delivery technologies (oral, transdermal, inhalation, and parenteral) are focusing on boosting sales volume through improved safety and efficacy.

Dental Consumables and Equipment

The adoption of emerging technologies which help reduce the overall turnaround time for dental procedures while improving their efficiency is expected to drive this market in the coming years. Computer-aided design (CAD) and computer-aided manufacturing (CAM) technology is increasingly being used in the dental industry as it offers better precision for dental restorations, and cosmetic dentistry.

The dental industry can be categorized into two major segments, namely dental consumables and equipment. Dental consumables include dental bridges, dental implants and prosthetics, crowns, biomaterials, adhesives, orthodontics, periodontics, infection control, and other consumables. The dental equipment category includes lasers, radiology, laboratory, sterilization, CAD/CAM, electrosurgery.

Mobility Aid Technologies Market Research Reports & Consulting

The mobility aid market is growing rapidly due to increased life expectancy and the percentage share of the aged population, with products such as wheelchairs, stair lifts, and scooters.

Microfluidics

The field of drug discovery forms the major application market for microfluidic technologies, that facilitate higher throughput and decrease the time and cost of analysis.

Applications of this technology includes biochips, miniature pressure sensors, sample processing units for microarrays, patch clamping chips for screening drug candidates with ion channel targets, and target-amplification units for nucleic acid assay systems.

Bioimplants, Neuro-stimulation

A bioimplant is a surgically implanted biomaterial used to replace damaged tissue in the human body, such as cardiac and orthopaedic uses.

A neuro-stimulator is an implant that helps reduce the experience of pain by replacing it with a tingling sensation, mainly used for the treatment of Alzheimer’s, Parkinson’s disease, chronic pain management, and for chronic heart failure, and the treatment of depression.

The neuro-stimulation market includes product categories such as spinal cord stimulator, deep brain stimulator, vagus nerve stimulator, sacral nerve stimulator, and gastric electrical stimulator.

Cardiovascular Devices

Cardiology devices are medical devices (Cardiac Monitoring, Cardiac Surgery, Electrophysiology and Ablation Devices, and Interventional Cardiology and Peripheral Vascular devices) intended to use for diagnosis, treatment and monitoring of cardiovascular system and diseases.

Key factors driving growth include rising aging population, increasing incidence of cardiovascular diseases, rising patient awareness levels, and increasing demand of minimally invasive procedures.

Ambulatory ECG monitoring and mobile cardiac telemetry, are becoming increasingly important in both home care and clinical settings to detect uncommon symptomatic signs, in a way that does not restrict patient mobility while simultaneously providing data.

The Cardiac Monitoring devices segment is categorized into electrocardiogram (ECG) devices, event monitors, implantable loop recorders (ILR), and cardiac output monitoring (COM) devices. The Cardiac Rhythm Management devices segment is categorized into defibrillators, pacemakers, and cardiac resynchronization therapy (CRT) devices.

Cardiology procedures include, Percutaneous Transluminal Coronary Angioplasty (PTCA), Percutaneous Transluminal Angioplasty (PTA), Endovascular Aneurysm Repair (EVAR), Guiding Catheters, & Intravascular Ultrasound (IVUS) Catheters/Optical Coherence Tomography (OCT) Catheters, Permanent and Retrievable Inferior Vena Cava (IVC) Filters, Pediatric Interventional Cardiology.

Cardiac surgery devices segment can be categorized into on-pump CABG perfusion circuit devices, off-pump CABG devices, endoscopic vessel harvesting devices, anastomosis-assist devices, heart valves, percutaneous heart valve therapy (PHVT) devices, heart valve repair devices, and ventricular-assist devices.

The Electrophysiology and Ablation Device segment are categorized into Electrophysiology Diagnostic Catheters, and Electrophysiology Ablation Catheters.

Interventional Cardiology and peripheral vascular devices can be categorized into eight segments: angioplasty stents, catheters, angioplasty balloons, Endovascular Aneurysm Repair (EVAR) Stent Grafts, Inferior Vena Cava (IVC) Filters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and accessories.

Bioabsorbable stents is also one of the emerging technology, capable of reducing post-surgical risks associated with restenosis.

In-Vitro Diagnostics

IVD plays a key role in healthcare for predictive testing, diagnosis, screening, and treatment monitoring. Factors such as the continuous technological advancements in the field of diagnostics and an increase in healthcare awareness have made IVD testing an indispensable tool in early diagnosis. The development of a large variety of reagents and analytical techniques are the other factors leading to the growth in the IVD market, and this trend is expected to continue in the future, with an increasing trend towards the total laboratory automation (TLA) and modular automation to minimize non-value-added steps.

In vitro diagnostics (IVD) tests are medical devices, instruments, reagents, samples of blood, urine, saliva, tissue, stool, and cerebrospinal fluids, used to determine medical information for the diagnosis of a disease.

Based on the technology, the IVD market is segmented into clinical chemistry, immunochemistry, hematology, coagulation, microbiology, molecular diagnostics.

Based on applications, the IVD market is segmented as diabetes, infectious diseases, AIDS, drug testing, oncology, cardiology, nephrology, auto-immune diseases.

Based on product types, the IVD market has segments like instruments, reagents, data management software/hardware, and services.

The end-user segment of the IVD market comprises of Laboratory testing, hospital testing, academic testing, point-of-care testing, patient self-testing.

Increasing interest in personalized medicine, increasing application of genetic testing in the diagnosis of oncology and infectious diseases, increasing number of hospitals, increasing healthcare spending from emerging countries and technological advancements in genomics, proteomics, and molecular pathology is driving interest of the companies in the IVD market thereby creating new market opportunities.

Over the past few years, small players with exclusive technology have been acquired by key players to boost their product portfolio. The key players include Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), Dickson and Company (U.S.), Siemens Healthcare (Germany), Roche Diagnostics Limited (Switzerland), Becton, Diagnostica Stago SAS (France), Danaher Corporation (U.S.),

More than any other technology, biotechnology has the potential to alter our lives in a positive way, by delivering new levels of health, prosperity and sustainability across the world.

The Biotechnology Market is estimated to reach $ 730 billion by 2025; growing at a CAGR of 8.1% to 2025.

Biotechnology tools and instrumentation have given rise to various interdisciplinary fields such as bioinformatics and pharmaco-genomics, having applications in chemotherapy, microarray technology, immunoassay, electrophoresis, and mass spectrometry, and have revolutionized the fields of drug delivery, drug discovery, and personalized medicine.

Increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, recombinant technology, and DNA sequencing are the factors driving growth.

Decreasing prices of DNA sequencing is expected to drive growth, by encouraging researchers and manufacturers to increase R&D initiatives targeted at researching genetic variations and developing therapeutic solutions for chronic diseases, such as cardiovascular diseases, diabetes, and cancer.

But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

Key players operating in the market are Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co., Inc., Sanofi, Abbott Laboratories, Amgen Inc., AstraZeneca, Biogen, and Celgene Corporation, among others.

The biotechnology sector studies cover the most prominent companies pursuing the advent of novel biotechnological products.

Our reports identify investment opportunities to be capitalized on in the medical technology, medical devices and biotechnology sectors. Research covers the technology markets within the new and emerging fields of genomics, proteomics, bioinformatics, biomarkers, biomaterials, and biosimilars.

Biomaterials

Biomaterials are used in wound-care to replace damaged tissues in the body and initiate tissue regeneration. Being mostly biodegradable, are also used as surface coatings for medical implants and devices.

The biomaterial market currently generates more than billion globally, and is expected to grow the next few years. Orthopedic applications form the largest segment of the overall biomaterials market. Polymer-based biomaterials, biochips and biosensors are expected to drive future market growth.

Genomics, Proteomics | Bioinformatics & Biomarkers

Genomics research covers genomics technology markets for genotyping, multiplexing, real time polymerase chain reaction, and single nucleotide polymorphisms, as well as predictive medicine and pharmacogenomic testing, with applications in Alzheimer’s disease, neurofibromatosis, polycystic kidney disease, and breast and ovarian cancer.

Proteomics research that involves the analysis of proteins and protein structures, covers the markets for proteomics-based diagnosis and therapy, and technologies such as microarrays, protein chips, and 2D electrophoresis. Drug discovery forms the highest revenue-generating application market of proteomics.

The Bioinformatics market is witnessing growth due to the increasing demand for data handling tools in drug discovery, and the rapid growth in the fields of proteomics and genomics.

  • Bioinformatics tools market (sequence analysis, alignment, manipulation) Bioinformatics applications market (molecular medicine, preventive medicine, and drug development)

  • Bioinformatics content/database market (primary sequence, protein sequence, genome, and microarray databases)

Biomarkers play a key role in drug discovery, submarkets such as drug targets, ADME-TOX profiling, and process quality assurance in drug development.

Biomarkers also play key role in diagnosis, and the biomarker applications segment covers markets such as personalized medicine and the diagnosis and treatment markets for various disease conditions such as cancer, cardiovascular diseases, neurological disorders, and autoimmune diseases.

The biomarker technologies segment is classified into the pre-genomic (enzyme and metabolite assays, molecular diagnostics, immunodiagnostics) and post-genomic (transcriptomics, metabolites and imaging biomarkers) technology markets.

The biomarker services segment caters for pre- and post-clinical services, such as sample preparation, mRNA analysis and miRNA analysis, antibody development, assay development and production, and validation and reporting.

Stem Cell

The stem cell market is growing fast, being boosted by the personalized medicine application of stem cell therapy. The stem cell therapy market, is including cord blood cells, induced pluripotent stem cells, and haematopoietic stem cells, and stem cell application markets include spinal cord injury, cancer, rheumatoid arthritis, myocardial infarction, and limb ischemia.

Tissue Regeneration

The tissue regeneration market for cardiovascular, urologic, organ regeneration, wound care, orthopedic and neurologic segments, tissue regeneration, is expecting promising growth.

Food Biotechnology

Biotechnology-enabled improvements in microbial processes have significantly enhanced the quality and nutritional value of food and beverage products.

The pharmaceuticals market is experiencing growth in sales and in R&D investments, due to the worldwide increase in life expectancy, as well as the increasing incidence of chronic and infectious diseases.

The Pharmaceutical Industry is one of the major innovators, with increasing focus on the development of new molecules, biotechnology and the adoption of new technologies that provide ensure the longevity of the population.

The pharmaceutical industry is one of the larger global industries, which generates almost one trillion U.S. dollars of revenue worldwide.

Branded, patented medicines by far make up the largest share of pharmaceutical revenues. On the other hand, generics are of substantial importance for the availability of medicines to large parts of the population.

Since the global population and life expectancy are steadily increasing, the pharmaceutical industry is destined for growth. On the other hand, pharmaceutical companies are under pressure from generic manufacturers or spending cuts by national health policies, while striving to employ a more knowledge-centric approach to new drug development, disease diagnosis, management, and treatment.

Pharmaceutical companies are facing challenges from emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations.

In addition, long clinical trials, strict regulatory processes, and high treatment costs are restraining growth.

Entry of generic drugs that are less expensive has posed threat to the market players in the drugs market. Increasing safety requirement and legislation is furthermore adding pressure on the drug and therapy providers to increase efficiency.

More than any other industry, the pharmaceutical sector is highly dependent on its research and development segment. There is significant increase in the demand for innovative drugs which drives R&D investment in the Pharmaceutical Industry across developed and developing countries. The top pharmaceutical companies invest up to 20% of their revenues in R&D measures.

Our reports deliver information associated with the manufacturing of pharmaceuticals, distribution, and marketing activities, and address all aspects of this sector such as drivers, challenges and competitive outlook.

Leading players from the United States are Pfizer, Johnson & Johnson, Merck and Abbott. Novartis and Roche from Switzerland, GlaxoSmithKline and AstraZeneca from the United Kingdom, and French Sanofi are the European big five.

The Therapeutics and Drugs Market

Innovation in breakthrough technologies has speeded up development of the therapeutics and drugs market.

There has been a shift in focus from providing general drugs providing drugs for target cluster and personalized therapies.

Technologies such as proteomics, genomics, and personalized medicines have led a long way in introducing effective drugs and therapies.

Increasing regulations imposed on drug development process have created a demand for automated tools such as bioinformatics that can store analytical data and facilitate the researcher to design and develop effective drugs.

Oncologics continue to generate the largest amount of revenue among all therapeutic classes.

Other best-selling therapeutic classes for the pharmaceutical industry are pain drugs, antihypertensives and antidiabetics.

The pharmaceuticals industry is dominated by the U.S., but emerging economies like in China and India are expected to show a double digit growth, in the outsourcing R&D sector.

Our market research on pharmaceutical outsourcing, is including market share, market segmentation data and growth trends.

Drug Development & Discovery

The emergence of biopharmaceuticals has opened a new arena for drug discovery; and breakthroughs in the fields of proteomics and genomics have also enabled drug manufacturers to develop more effective drugs and therapies.

The drug development market encompasses pharmacokinetics, lab automation, biosensors and detection technologies, imaging technologies, microfluidics and others.

The digitization in biomedical research offers lucrative prospects for growth.

Recent developments in the field of genomics, molecular biology, and biotechnology have created an environment fostering growth. However, tapping into these lucrative prospects is not easy, as it requires large initial investment. Delayed approval processes and stringent regulations hinder growth prospects.

Drug discovery markets include gene expression profiling, SNP genotyping, antibody-based technologies, genetic surrogate for drug action, biochips and microarrays tissue screening, combinatorial chemistry, target validation technologies.

Also RNAi technology (siRNAs, miRNAs, dsRNA, shRNA, ddRNAi, MicroRNA) is used to accelerate drug discovery while lowering drug attrition rates.

Clinical Trials

Increasing demand for personalized medications and globalization of clinical trials are the drivers in the clinical trials market. In addition, the patent expiry of blockbuster drugs and the emergence of biosimilars have spurred growth prospects in the clinical trials market.

Drug Delivery

Drug delivery systems use chemical or physiological triggers to control the administration of medication, including delivery technologies for active transdermal drug delivery, cell and gene therapies, controlled release preparations, and protein and peptide delivery.

Our market studies cover novel treatments in therapeutic areas, ranging from cardiovascular and gynecological to orthopedic and neurological, among others. We focus on the upcoming technologies in drug delivery and provide insights into areas to help you boost sales and sustain growth We also analyze how smart chemistry is utilized in developing polymer-based drug delivery systems, their design, synthesis, and application from a therapeutic efficacy viewpoint, and highlight the next generation nanomedicine strategies based on this novel chemistry.

Biosimilars

Biosimilars are new versions of generic pharmaceuticals, that act differently from their predecessors due to differences in molecular structures and preparation methods.

Unlike generic medicines, manufactured through chemical synthesis, biologic medicines contain one or more active principles produced or derived from a biologic source, include a wide range of products like vaccines, allergens or recombinant proteins.

Rodríguez de la Cuerda AL

Weight Management

The weight management market is still accelerating to identify alternative artificial sweeteners that can preserve the traditional flavours in diet foods, beverages and confectionaries.

However, online sales of fictitious and banned products has increased, holding back market growth for genuine products.

Vitamins & Dietary Supplements

The demand for vitamin and dietary supplements has risen considerably in developed countries, and the market players are capitalizing on the lucrative prospects across emerging nations to sustain growth.

Pharmacies

Pharmacies are responsible for compounding and dispensing as well as assisting with information on the safe and efficient usage of pharmaceuticals.

Our reports provide key statistics and analysis on market operating conditions, business challenges, current and historical industry growth trends, and more. They offer an explanation of the structure of the industry and analysis across the value chain, market sizes, revenue growth, market and product trends, demographics, price trends, product/company rankings or comparisons, key players profiles, comparing national and multinational operators by sales, market share, investments, projects, partners and expansion strategies,designed to provide a better understanding of a market's competitive landscape, and market forecasts, projecting how current trends will influence industry sales and consumption patterns in the future, latest market developments and analyzing the potential effects of regulatory changes in conjunction with the background macroeconomic outlook.